Published in Br J Cancer on April 26, 2016
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science (2010) 4.56
cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor. J Virol (2001) 2.50
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol (2006) 1.67
Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res (2007) 1.45
Transcriptomes of human prostate cells. BMC Genomics (2006) 1.42
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia (2010) 1.36
The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat Rev Cancer (2013) 1.31
Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther (1999) 1.22
Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci (2004) 1.18
Novel innate immune functions of the whey acidic protein family. Trends Immunol (2008) 1.16
Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis (2008) 1.13
PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer (2006) 1.11
Smooth muscle-epithelial interactions in normal and neoplastic prostatic development. Acta Anat (Basel) (1996) 1.09
Stroma-epithelium crosstalk in prostate cancer. Asian J Androl (2008) 1.07
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res (2005) 0.98
Novel insights into the biology of interleukin-32. Cell Mol Life Sci (2013) 0.97
Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res (2003) 0.97
Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev (2008) 0.96
The WFDC1 gene encoding ps20 localizes to 16q24, a region of LOH in multiple cancers. Mamm Genome (2000) 0.96
Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer. Prostate (2005) 0.94
Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle. J Biol Chem (1998) 0.89
Decreased stromal expression and increased epithelial expression of WFDC1/ps20 in prostate cancer is associated with reduced recurrence-free survival. Prostate (2004) 0.89
Lipocalin-type prostaglandin D synthase in human male reproductive organs and seminal plasma. Biol Reprod (1998) 0.88
The WFDC1 gene: role in wound response and tissue homoeostasis. Biochem Soc Trans (2011) 0.84
Purification of a novel protein (ps20) from urogenital sinus mesenchymal cells with growth inhibitory properties in vitro. J Biol Chem (1995) 0.83
Molecular analysis of WFDC1/ps20 gene in prostate cancer. Prostate (2004) 0.82
Tumor apoptosis in prostate cancer by PGD(2) and its metabolite 15d-PGJ(2) in murine model. Biomed Pharmacother (2012) 0.79
Prostaglandin D2 synthase enzymes and PPARgamma are co-expressed in mouse 3T3-L1 adipocytes and human tissues. Prostaglandins Other Lipid Mediat (2003) 0.78